Prescription Dermatology
Roflumilast Cream (ZORYVE)
Topical PDE4 inhibitor for psoriasis, AD, and seborrheic dermatitis
Duration
topical1 days1 sessions
Downtime
なし
Sessions
8 weeks前後で初期評価
About This Treatment
Topical roflumilast is a nonsteroidal PDE4 inhibitor that reduces inflammatory signaling. Efficacy has been shown in DERMIS and ARRECTOR psoriasis programs, including scalp involvement.
Mechanism of Action
PDE4 inhibition elevates intracellular cAMP and suppresses pro-inflammatory mediator production such as TNF-α.
Indications
General indication (see detailed description)
Expected Results
Phase 3 trials reported significant improvements in body/scalp psoriasis and early itch reduction.
Clinical Evidence
Stein Gold L, et al. (2025)
Roflumilast foam 0.3% in scalp/body psoriasis (ARRECTOR phase 3). JAMA Dermatol
Clinical improvement was reported in this study (see original paper for details).
DERMIS investigators (2025)
Pooled phase III PASI outcomes with roflumilast cream 0.3%. Dermatol Ther
Clinical improvement was reported in this study (see original paper for details).
U.S. FDA (2025)
ZORYVE prescribing information. FDA label
Clinical improvement was reported in this study (see original paper for details).
Risks & Side Effects
Diarrhea, headache, nausea, and application-site pain may occur. Use cautiously in patients with relevant hepatic impairment per labeling.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition